Quantum Cyber N.V. is a Nasdaq-listed autonomous defense technology company building an artificial intelligence (AI)-powered, quantum-accelerated "system-of-systems" platform spanning drone warfare, counter-UAS (unmanned aerial systems), and border security. Formerly Mainz Biomed N.V., the company pivoted into defense technology in 2026, a repositioning that places it at the intersection of two high-visibility themes: AI-driven autonomy and quantum-enhanced navigation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company's competitive positioning rests on vertical integration rather than organic product development. By securing an exclusive license to an autonomous drone portfolio, acquiring a roughly 50,000-square-foot manufacturing facility in Bridgeport, Connecticut, and installing an 80-unit 3D-printing drone production line, management is attempting to control design, production, and cost structure under one entity. A Nevada-based subsidiary, Quantum Drones Corporation, is structured to help address foreign ownership, control, or influence (FOCI) rules that govern access to sensitive U.S. defense programs.
That said, the competitive moat remains unproven. The platform is assembled from licensed and acquired technologies, and the company's target of up to 100,000 drones in annual production is a forward-looking management projection, not current operational capacity. Rival incumbents and established primes have deeper engineering benches, classified-approval track records, and program-of-record relationships that a small-cap entrant must still earn.
The near-term trajectory hinges on whether strategic announcements convert into contracted, recurring revenue. The most consequential catalysts include contract conversion from LOIs with General Cherry and SOCOM into binding procurement awards, upcoming quarterly reports that will clarify revenue recognition and margins, intellectual property milestones such as the licensed quantum antenna for GPS-denied environments, a potential acquisition pipeline using debt-free capital, and any expansion in thin analyst coverage that currently shows one "Buy" rating with a $9 price target alongside a prior "Hold" downgrade.
The company's outlook is tightly coupled to U.S. defense budgets and doctrine. The proposed fiscal 2027 allocation — approximately $55 billion for drone and autonomous warfare — reflects a structural shift toward "attritable autonomy," the mass-produced, lower-cost systems validated in Ukraine. Policy tailwinds include an executive order on American drone dominance and "Buy American" preferences that could favor the company's U.S. facility. The counter-UAS market is projected to grow from roughly $3.1 billion to $10.6 billion by 2030, a compound annual growth rate near 27%, according to third-party estimates cited by the company. Offsetting these are interest-rate sensitivity for a pre-revenue firm, export-control burdens, long procurement cycles, and opportunities in Middle East and Gulf channels that carry regulatory complexity. From what I see, this macro backdrop is important because it sets the stage for any early-stage player in this space.
Looking toward 2026 and beyond, the defining question is whether Quantum Cyber can move from a strategically assembled platform to a genuine defense manufacturer. Several structural themes will shape that transition: market expansion into border security and allied channels, cost and margin evolution through vertical integration, technology transitions around the quantum antenna and swarm operating system, competitive threats from large primes, and capital allocation that balances a debt-free balance sheet against potential dilution from acquisitions or R&D. Analyst expectations remain early and thinly sourced, with the single $9 price target implying substantial upside but reflecting one firm's view. As disclosures on contracts and production arrive, sentiment could shift rapidly.
The Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, exchange-traded fund (ETF), or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors monitoring early-stage defense names such as Quantum Cyber, the engine offers one data-driven lens for tracking emerging price behavior alongside fundamental catalysts. In my view, this has been a useful addition to my own research workflow when following names like this one.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Oscillator for QUCY moved into overbought territory on October 12, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 68 cases where QUCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +4.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where QUCY advanced for three days, in 150 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
QUCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QUCY as a result. In 98 of 109 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for QUCY turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 40 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
QUCY moved below its 50-day moving average on October 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for QUCY crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QUCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for QUCY entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. QUCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.631) is normal, around the industry mean (72.578). P/E Ratio (0.000) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. QUCY's P/S Ratio (60.976) is very high in comparison to the industry average of (9.775).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QUCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalSpecialties